Axsome sold a lot more medicine over six months and still lost more money.
Revenue rose 45.5% from the comparable period to $218.4 million, helped by higher net product revenue from AUVELITY, SUNOSI, and SYMBRAVO. The operating loss widened to $49.6 million from $36.7 million, while the net loss reached $51.3 million from $48.0 million.
The income statement is not quite as harsh as those dollar losses suggest. Operating margin improved to negative 22.7% from negative 24.5% as sales grew faster than operating expenses. But the business still spent more than it earned, and diluted shares rose 4.8% to 51.8 million.
Cash generation did improve. Operating cash outflow narrowed to $53.7 million from $75.8 million, and cash ended the period at $319.9 million, up from $303.0 million. Management tied the smaller outflow to product revenue, partly offset by commercial and clinical spending.
"The decrease of $22.1 million was primarily due to higher net product revenues from AUVELITY, SUNOSI, and SYMBRAVO, which was partially offset by increased cash used for commercial and clinical-related activities."
10-Q 2026-08-10
That is the central tradeoff in the six-month numbers: products are producing more revenue, but commercialization is still carrying a meaningful cash cost.
The balance sheet adds a more physical version of the same tension. Inventory climbed 105.4% to $37.9 million, more than twice the rate of revenue growth. Accounts receivable rose 39.5% to $277.5 million. The company does not disclose the cause of those balance-sheet changes in the supplied results.
Some spending also moved toward the pipeline. Axsome said the six-month increase in costs was primarily tied to the AXS-20 asset acquisition, partly offset by lower AXS-05 spending because of clinical-study timing.
"The increase for the six months period was primarily due to asset acquisition costs related to AXS-20, which were partially offset by lower spending on AXS-05, driven by the timing of clinical study activities."
10-Q 2026-08-10
That helps explain why revenue growth has not yet translated into a smaller operating loss in dollars. The company is selling established products while adding commercial activity and continuing to fund future candidates, with some costs arriving unevenly across periods.
Axsome's recent annual results show the scale of the commercial ramp: revenue reached $638.5 million in 2025, while operating margin improved to negative 26.1%. The stock had risen 106.0% over the prior 12 months through August 7, and the company carried an enterprise-value-to-sales ratio of 16.3x. Those figures put the filing's unresolved question in plain terms: how much of the sales trajectory arrives with durable cash generation rather than a larger operating footprint.
Axsome's next quarterly report will provide the next comparison for inventory, accounts receivable, operating cash flow, and the dollar size of the operating loss.
The unresolved tension is simple: Axsome is growing revenue faster than its margins and working capital are settling.